There has been a remarkable increase in prescription rates of antipsychotics in children and adolescents in recent years. Their side effects are a neglected area of research in this population, despite its vulnerability. In this cross-sectional study, we compared the presence of side effects in 60 children and adolescents who had taken antipsychotic medication for less than 1 month and 66 who had been receiving treatment with antipsychotics for more than 12 months. Mean age for the total sample was 15.62 years (SD 1.85). Groups did not differ in age, gender, or diagnosis. A total of 21.7% of short-term treatment group patients and 37.9% of longer-term treatment group patients presented mild dyskinetic movements (p ‫؍‬ 0.004). Hyperprolactinemia was present in 78.6% and 48.5% in the short-term and longer-term treatment groups, respectively. Body mass index (p Ͻ 0.001), cholesterol levels (p Ͻ 0.001), and lowdensity lipoprotein-cholesterol (LDL-C) (p ‫؍‬ 0.018) were higher in the longer-term treatment group. The use of these drugs in these populations merits careful scrutiny. 487 
INTRODUCTION I
N RECENT YEARS, there has been a remarkable increase in prescriptions of antipsychotics in children and adolescents, mainly for nonpsychotic disorders, despite the lack of indications for these drugs in these age groups (Patel et al. 2002) . It is not only the lack of efficacy studies in children and adolescents, but also the fact that their safety and tolerability profiles have not been thoroughly assessed, that should concern physicians treating pediatric patients with these drugs. The higher prescription rates in this population are due mainly to an increase in the use of second-generation antipsychotics (SGAs) and also to their use as nonspecific treatment for conduct disorders associated with a variety of neuropsychiatric disorders. A recently published retrospective cohort study conducted in the United States (Cooper et al. 2004) showed that the proportion of children who became new users of antipsychotics nearly doubled from 1996 to 2001, with a substantial increase in use of these drugs mainly for nonpsychotic disorders. In some areas in the United States, prescription rates of these drugs in children and adolescents showed a 63% increase from 1990 to 1996, and up to a 160% increase in prevalence from 1996 to 2000, attributed to the more widespread use of SGAs (Patel et al. 2002; Curtis et al. 2005) .
The severity of the potential side effects of antipsychotic drugs, as demonstrated in previous studies in adults (Glazer 2000; Kane 2004 ), makes it necessary to be particularly careful with their appearance in this vulnerable young population.
Drug-related extrapyramidal symptoms, which can be extremely impairing, are one of the main reasons for poor treatment compliance (Hoge et al. 1990) . There are few studies on the presence, duration, characteristics, and risk factors for the development of these side effects in pediatric populations, in part due to methodological difficulties (different measurement methods, small sample sizes, variable time of exposure to antipsychotics, etc.) (Stigler et al. 2001) . Prevalence rates of acute dystonic reactions in children and adolescents treated with first-generation antipsychotics (FGAs), reported in the few studies available, are thought to be around 16-17% (Campbell et al. 1984) . Prevalence of parkinsonism has not been well established in patients under the age of 18; Richardson et al. (1991) found 6-month prevalence rates of 34% for parkinsonian signs in 61 hospitalized children and adolescents exposed to FGAs. Apparently, rates are similar to those in adults, or even slightly higher, although traditionally, parkinsonism is expected to increase with age.
To date, tardive and withdrawal dyskinesias related to antipsychotic treatment have been more thoroughly studied in children and adolescents. Prevalence rates vary from 12% to 29% (Kumra et al. 1998; Locascio et al. 1991) with FGAs, and 0% with SGAs (Turgay et al. 2002) , meaning they are presumably far less common than in adult populations (Gerlach 1988 ). It has also been shown that these symptoms are less severe in children and adolescents, and usually reversible 3-12 months after discontinuation of the antipsychotic drug (Owens 1995) , but these findings require further study, as no direct comparison of dyskinesias in children and adults, within the same study, has been published to our knowledge. As for akathisia, there are only a few studies available, and they seem to show lower rates of this symptom in children and adolescents (average of about 5%) than in adults (from 20% to 45%) (Sachdev 1995) with FGAs. Neuromotor side effects of SGAs in children and adolescents have been less thoroughly studied, and, although available data suggest that SGAs are safer in this area (Sikich et al. 2004; McDougle et al. 2005) , prevalence rates have not been well established. Most of the studies previously published have been conducted in the United States, where there is a high rate of polypharmacy in this population, which interferes with interpretation of results, as many other widely used drugs, such as stimulants, may cause such side effects.
Metabolic and endocrine side effects of antipsychotic drugs, especially SGAs, have become a major cause of concern in recent years (Newcomer 2005) . Again, the risk of developing metabolic and endocrine dysfunction is also present for children and adolescents. Increased prolactin serum levels, often seen with FGAs, have also been described in pediatric populations with the newer drugs, and their possible long-term repercussions on bone density and sexual function remain uncertain (Wudarsky et al. 1999; Findling et al. 2003; Pappagallo and Silva 2004) . The same applies to weight gain (Baptista et al. 2004; Stigler et al. 2004; Vieweg et al. 2005 ) and hyperglycemia (Lindenmayer et al. 2001) . Dyslipidemia, including hypercholesterolemia and hypertriglyceridemia, has been described in association with SGA treatment, as well as with schizophrenic disorders (Huang and Cheng 2005) . All of these metabolic changes imply a higher risk of cardiovascular morbidity and mortality in adult life, but the truth is that their presence and impact in child populations have scarcely been assessed. Some degree of thyroid dysfunction has also been associated with schizophrenia and with certain SGAs, such as quetiapine (Kelly and Conley 2005) .
In view of the previously published data and our own clinical experience, we hypothesized that treatment with antipsychotic drugs in children and adolescents induces relevant metabolic and extrapyramidal side effects. To test our hypothesis, we compared a group of patients who had received antipsychotics for fewer than 30 days with a group exposed for more than 1 year, matched for gender and sex. Other aims of the study were: (1) to describe the presence of abnormal involuntary movements in this population and determine whether involuntary movements are present early in antipsychotic treatment; (2) to describe the presence of metabolic side effects; (3) to identify possible risk factors for the development of these side effects; and (4) to describe other side effects in this age group.
METHODS

Sample
Patients were selected from a larger, longitudinal study that was conducted in a catchment area comprising two short-term inpatient units, one located in a general hospital and the other in a pediatric hospital. Each of them has 20 beds. The two units cover the admission needs of the entire State of Madrid (population approximately 4.5 million). Patients were also selected from three child and adolescent outpatient psychiatric clinics in the same catchment area, to recruit patients with a variety of mental disorders and different treatments. Inpatients and outpatients in these units were recruited amongst consecutively treated patients who met the inclusion criteria, between May, 2003, and May, 2005. Written informed consent was obtained from parents or guardians and verbal consent was obtained from patients. Inclusion criteria consisted of treatment with any antipsychotic drug, either for less than 1 month or for more than 12 months, regardless of diagnosis, in patients aged 7-18 years. For the short-term treatment group, the limit of less than 1 month of exposure to antipsychotics was based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) (American Psychiatric Association 2000) criteria for diagnosis of neuroleptic-related tardive dyskinesia, which requires at least 3 months on antipsychotics to diagnose this movement disorder for adults and 1 month for patients over 60 years of age. The study was approved by the institutional review board at the two hospitals.
Assessment
Demographic data were collected prior to assessment for both subgroups, along with information about personal history of prior head injury, epilepsy or seizures, and multiple streptococcal pharyngitis, through interviews with patients, parents, and/or chart reviews. Presence of positive psychotic symptoms was assessed clinically by the psychiatrists in charge of each patient. Also, familial history of multiple streptococcal pharyngitis and rheumatic fever, as well as Parkinson's disease and Gilles de la Tourette's syndrome, heart disease, diabetes, or psychiatric disorders was gathered. Substance use information was assessed through chart review and with a structured interview with yes/no questions, administered to patients and relatives. Psychiatric diagnoses were made by child and adolescent psychiatrists, based on International Classification of Diseases (ICD-10) criteria.
The presence of involuntary movements was assessed with the Involuntary Movement Scale (IMS), created and validated at the Maryland Psychiatric Research Center (Baltimore, Maryland) (Cassady et al. 1997) . The scale comprises 28 items to evaluate dyskinetic movements, parkinsonian tremors, and rigidity, and 3 items to rate global impression of dyskinesia, parkinsonism, and akathisia. Each item is rated from 0 to 7 (absent-maximum severity). One of the psychiatrists (P.L.) was trained by the authors of the scale with an interrater reliability, intraclass correlation coefficient (ICC), of 0.8 to 0.9 for the different items of the scale. All of the assessments were made by two psychiatry residents and the aforesaid psychiatrist, with interrater and intrarater reliability assessments performed periodically (ICC from 0.80 to 0.90 for the different scale items between raters). Raters were not directly involved in clinical psychiatric management of patients.
We calculated a total dyskinesia score, adding up all ratings on dyskinesia items (jerky tongue movements; lip smacking or pouting; tic-like eye movements; grimacing and irregular movements of the jaw; jerky, irregular finger and wrist movements; jerky arm movements; shoulder and neck shrugging and jerky movements; jerky movements of feet and toes; heel walking; exaggerated arm swing while walking; pelvis projection and involuntary movements of the diaphragm), and also a total parkinsonism score (regular tongue tremor; decreased salivation; regular lip tremor; perioral tremor, and loss of eye-blink; masked facies; jaw tremor; pill rolling tremor and regular resting tremor in fingers and wrists; muscular rigidity in arms and legs; regular arm tremor; leg tremor; diminished arm swing and rigidity while walking; and shuffling gait). In these total scores, ratings of 1 (questionable or doubtful presence of movement disorder) were considered as absence of abnormal movements, and therefore were not included in the total sum. Scores of 2 or more were considered as presence of movements.
We maintained a medication tracker in which all medications ever taken by the patient at the time of assessment and the prescribed intervals and doses were noted; this information was obtained from clinical charts and interviews with parents or guardians.
Height, weight, and blood pressure of each patient were collected, together with the following fasting blood test data-prolactin, glycosylated hemoglobin, thyroid hormone, glucose, triglycerides, and cholesterol levels. Blood samples were collected for all cases early in the morning, after giving specific instructions to parents or guardians about the importance of fasting. All tests were processed in the same laboratory at the same hospital.
We also gathered subjective information from the patients, using a structured interview with yes/no questions, about other side effects, such as sleepiness, headache, nausea and/or vomiting, dizziness, increased or decreased appetite and salivation, blurred vision, and rhinitis.
Statistics
We used chi-square tests to compare qualitative variables between groups, with Fisher's exact tests when more than 20% of the cells had fewer than 5 subjects. We compared quantitative variables using t-tests and analyses of variance (ANOVA), with Kruskal-Wallis or Mann-Whitney non-parametric tests when appropriate. We used Pearson and Spearman correlation tests to assess correlation of variables with and without normal distribution. As the two groups differed in the number of patients treated with mood stabilizers, the comparison of the (involuntary movement scale IMS) items between the short-term and longer-term treatment groups was repeated, controlling for the concomitant use of mood stabilizers. Due to the fact that the IMS items are not normally distributed, we used non-parametric tests (chisquare), performing the analysis first in the subgroup of patients that was on treatment with mood stabilizers, and then in the subgroup that was not on mood stabilizers, to check if the differences previously found in the total sample varied when adjusting for mood stabilizer treatment.
All statistical tests were two-tailed, with p Ͻ 0.05 considered statistically significant. We used the Statistical Package for the Social Sciences (SPSS) version 12.0.
RESULTS
Demographic and clinical characteristics
The study group consisted of 126 children and adolescents who met our inclusion criteria; group mean age was 15.62 years (SD 1.85, 7-18 years). There were 60 patients taking antipsychotics for less than 1 month (mean 5.8 Ϯ 7.06 days) and 66 patients taking them for more than 1 year (mean 27.46 Ϯ 19.54 months; median 19.66, 13-97 months). Clinical and sociodemographic data are presented in Table 1 . For each group of patients, we created a diagnostic variable, grouping diagnoses into psychotic disorders (46.7% in the short-term treatment group vs. 33.3% in the longer-term treatment group), affective disorders, including bipolar disorders and depression with psychotic features (18.4% vs. 18.2%), and other conditions (34.9% vs. 48.5%). There were no significant differences between groups ( 2 ϭ 2.429, df 2, p ϭ 0.297). Only 4 patients (6.7%) in the short-term treatment group and 6 patients (9.1%) in the longer-term treatment group had a co-morbid diagnosis with mental retardation ( 2 ϭ 0.253, p ϭ 0.615).
There were significant differences between both groups in variables such as cannabis use ( 2 ϭ 28.038, p Ͻ 0.001) and habitual week-end use of alcohol ( 2 ϭ 23.198, p Ͻ 0.001), which were more prevalent in the short-term treatment group. A past history of drug-related dystonic reactions and parkinsonian symptoms was significantly more common in the longerterm treatment group (21.2% for dystonias, 34.8% for parkinsonism) than in the short-term treatment group (5.0% for dystonias, 6.7% for parkinsonism) ( 2 ϭ 7.07, p ϭ 0.007; 2 ϭ 14.8, p Ͻ 0.001, respectively). There were no significant differences in prevalence of familial history of Parkinson's disease, tic disorders, or psychiatric disorders. Past personal history of multiple streptococcal pharyngitis, head trauma with loss of consciousness, and epilepsy or seizures showed no significant differences between groups (18.3%, 10%, and 6.7%, respectively, in the short-term treatment group; 19.6%, 15.4%, and 3.0%, respectively, in the longer-term treatment group). Presence of positive psychotic symptoms was significantly higher in the short-term treatment group (56.7% vs. 24.2%, 2 ϭ 13.54, p Ͻ 0.001).
In the short-term treatment group, only 2 patients (3.3%) were receiving treatment with FGAs, 44 (73.3%) were taking SGAs, and 5 (8.3%) a combination of both. In the longerterm treatment group, 5 of the patients (7.5%) were receiving FGAs, 53 (80.3%) SGAs, and 6 (9.1%) a combination of antipsychotic medications. Two patients out of this group (3%) were not taking any antipsychotic at the time of assessment. The differences between groups were not statistically significant (Pearson 2 ϭ 1.819, p ϭ 0.403). Mean dose and types of antipsychotic, and characteristics of concomitant medication taken by patients are summarized in Table 2 . Short-and longer-term groups were different with respect to total cumulative dose ANTIPSYCHOTICS SIDE EFFECTS 491 ODD ϭ oppositional defiant disorder; PDD ϭ pervasive developmental disorders; OCD ϭ obsessive compulsive disorder; SD ϭ standard deviation; ICD-10 ϭ International Classification of Diseases Ϫ10.
a No statistically significant differences between groups. b Statistically significant differences between groups (p Ͻ 0.0001).
[total chlorpromazine (CPZ) equivalents] of both FGAs (t ϭ 2.636, p ϭ 0.011) and SGAs (t ϭ 8.619, p Ͻ 0.001), and mood stabilizer cotreatment ( 2 ϭ 7.049, p ϭ 0.008). All of these variables were significantly higher in the longerterm treatment group, as shown in Table 2 .
Abnormal involuntary movements.
Considering the group as a whole, there were significant correlations between time of exposure to neuroleptics and global parkinsonism (rho ϭ 0.194, p ϭ 0.030), and global dyskinesia ratings (rho ϭ 0.235, p ϭ 0.008). Time of exposure to SGAs correlated with global dyskinesia rating (rho ϭ 0.269, p ϭ 0.002), total dyskinesia score (rho ϭ 0.283, p ϭ 0.001), global parkinsonism rating (rho ϭ 0.217, p ϭ 0.015), and total parkinsonism score (rho ϭ 0.244, p ϭ 0.006).
Lifetime CPZ equivalents correlated with global parkinsonism (rho ϭ 0.218, p ϭ 0.014) and global dyskinesia (rho ϭ 0.256, p ϭ 0.004) ratings, as well as with tic-like eye movements (rho ϭ 0.220, p ϭ 0.013), rigid facial expression (rho ϭ 0.230, p ϭ 0.009), hand tremors (rho ϭ 0.219, p ϭ 0.014) and jerky hand movements (rho ϭ 0.180, p ϭ 0.044), jerky arm movements (rho ϭ 0.371, p Ͻ 0.0001), arm rigidity (rho ϭ 0.204, p ϭ 0.022) and flaccid arms while walking (rho ϭ 0.227, p ϭ 0.01), and jerky neck and shoulder movements (rho ϭ 0.208, p ϭ 0.020). Total dyskinesia score also correlated significantly with lifetime CPZ equivalents (rho ϭ 0.284, p ϭ 0.001), but not with CPZ equivalent dose at the time of assessment.
A CPZ equivalent dose of antipsychotics at the time of assessment correlated, in the total group, with tongue tremor (rho ϭ 0.278, p ϭ 0.007), rigid facial expression (rho ϭ 0.227, p ϭ 0.29), arm rigidity (rho ϭ 0.210, p ϭ 0.045) and jerky movements (rho ϭ 0.259, p ϭ 0.013), and LAITA ET AL. 492 CPZ equiv. ϭ chlorpromazine equivalents; SD ϭ standard deviation; ns ϭ not significant.
flaccid arms while walking (rho ϭ 0.243, p ϭ 0.02), and with global parkinsonism rating (rho ϭ 0.278, p ϭ 0.007). We also found a significant correlation between total parkinsonism score and CPZ equivalent dose at the time of assessment (rho ϭ 0.244, p ϭ 0.019). The presence of abnormal involuntary movements, evaluated with the IMS, in the two subgroups, is shown in Table 3 . Only items that were positively rated in more than 5 patients have been included in this table. All involuntary movements observed were mild to moderate in intensity. A total of 25 patients (37.9%) in the longer-term treatment group and 13 (21.7%) in the short-term treatment group were rated as having mild dyskinetic movements on the global dyskinesia item ( 2 ϭ 8.393, p ϭ 0.004). Only 2 patients (3%) in the longer-term treatment group, and no patients in the shortterm treatment group, were rated as having moderate global dyskinetic movements. As for mild parkinsonian symptoms, 17 patients (25.8%) in the longer-term treatment group and 8 (13.3%) patients in the short-term treatment group were positively rated on the global parkinsonism item ( 2 ϭ 3.559, p ϭ 0.059). No significant differences were found in global akathisia ratings (1.7% in the short-term treatment group, 3.0% in the longer-term treatment group, 2 ϭ 0.372, p ϭ 0.542). In the short-term treatment group, global dyskinesia rating correlated with total time of exposure to antipsychotics (mean 0.2, SD 0.23 months of exposure; rho ϭ 0.279, p ϭ 0.031), and also with global parkinsonism rating (rho ϭ 0.284, p ϭ 0.028). Global dyskinesia and parkinsonism ratings correlated (rho ϭ 0.420, p ϭ 0.001). In this group, total SGA CPZ equivalents correlated with the presence of mild jerky arm movements (rho ϭ 0.264, p Ͻ 0.041), and lifetime FGA CPZ equivalents correlated with hand tremors (rho ϭ 0.300, p ϭ 0.020). No significant correlation was found between CPZ dose at the time of assessment and IMS items in the short-term treatment group.
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In the longer-term treatment group, CPZ equivalent dose at the time of assessment correlated significantly with ratings on the following IMS items: tongue tremor (rho ϭ 0.356, p ϭ 0.015), arm rigidity (rho ϭ 0.304, p ϭ 0.04) and jerky movements (rho ϭ 0.371, p ϭ 0.011), and flaccid arms while walking (rho ϭ 0.326, p ϭ 0.027); we also found a correlation with global parkinsonism rating (rho ϭ 0.293, p ϭ 0.048).
In both groups, diagnosis of a psychotic condition did not imply a higher rating on the IMS. Concomitant use of any of the psychotropic medications listed in Table 2 , including treatment with mood stabilizers, and also lithium and sodium valproate as single variables, was not related to any of the IMS subscores, nor with global scores. Due to the fact that mood stabilizer use differed significantly between groups, we compared the presence of involuntary movements in patients with and without mood stabilizer treatment. In the subgroup in treatment with these drugs, no statistically significant differences were found between short and longerterm patients in any of the IMS items. Instead, in the group of patients that was not taking mood stabilizers at the time of assessment, there were differences in the same items that figure in Table 3 for the total sample. Considering the global dyskinesia item as a continuous variable, we found statistically significant differences between groups (mean 0.22, SD 0.4, in the shortterm treatment group; mean 0.58, SD 0.84, in the longer-term treatment group. t ϭ Ϫ3.1, df 95.8, p ϭ 0.003). No significant differences were found between mean ratings on the global parkinsonism item in each group.
On the other hand, using Schooler and Kane criteria for tardive dyskinesia (Schooler et al. 1982) , 3 patients in the short-term treatment group (5%) and 13 in the longer-term treatment group (19.7%) had abnormal movements of mild severity (rating of 3) in at least two body parts. For the 3 patients in the short-term treatment group, the mean time of exposure to antipsychotics was 17.3 days, and they were all 17 years old; 1 patient was receiving risperidone, the second was on olanzapine but had taken risperidone previously, and the third one was on risperidone but had received haloperidol and zuclopenthixol in the previous days. The 13 patients from the longer-term treatment group were 15.4 years old on average, and their mean treatment exposure was 27.3 (SD 17.3) months. Six of them (46.15%) had taken FGAs (haloperidol, chlorpromazine, levomepromazine) at some time prior to assessment. At the moment of evaluation, only 2 patients were taking a combination of FGA and SGA, the rest of them were on SGAs. In this longer-term treatment group, fulfilling this Schooler-Kane criterion was not statistically associated with being on treatment with FGAs ( 2 ϭ 0.003, p ϭ 0.955). Using the aforementioned criteria, only 2 patients in the longer-term treatment group (3%) had a rating of moderate severity (rating of 4) in one body part. Both had been exposed to antipsychotic treatment for 60 months and, at the time of evaluation, both were being treated with risperidone. One of them (female, 17 years old) had a diagnosis of mental retardation and conduct disorder, and had been on treatment with haloperidol for up to 36 months prior to evaluation, and the other (male, 16 years old) had a diagnosis of Gilles de la Tourette's syndrome and had received thioridazine for several months prior to assessment. The latter patient also had a mild severity rating in at least two body areas. Therefore, the total tardive dyskinesia rate in the longer-term treatment group, summing up all patients fulfilling both Schooler and Kane criteria, would be 21.2% (n ϭ 14).
Subjective, metabolic, and endocrine side effects. Table 4 shows the prevalence of subjective adverse effects reported by patients in each group. Patients on longer-term treatment complained significantly more of increased appetite (27.3% vs. 10.0%, 2 ϭ 6.081, p ϭ 0.014) and decreased salivation (22.7% vs. 5.0%, 2 ϭ 8.066, p ϭ 0.005). Increased appetite was associated with higher body mass index (BMI) (t ϭ Ϫ2.640, df ϭ 60, p ϭ 0.004). There were no significant differences between groups for other subjective side effects.
There was no significant association between antipsychotic cumulative dose and type or concomitant medication and side effects reported by patients.
The main blood variables for the whole sample are summarized in Table 5 . Table 6 shows the number of patients presenting altered serum levels of glucose, total and low-density lipoprotein cholesterol (LDL-C) and triglycerides in each subgroup, and the mean values of those variables for patients with abnormal values in those parameters, considering both adult and pediatric thresholds for the diagnosis of the metabolic syndrome, following recommendations of the National Cholesterol Education Program of The National Heart, Lung and Blood Institute (2001) and recent guidelines for the metabolic syndrome in children and adolescents . No statistically significant differences between subgroups were found in the number of patients with altered levels for each of the measures, except for the number of patients with total cholesterol levels above 170 mg/dL, which was significantly higher in the longerterm treatment group ( 2 ϭ 17.15, df 1, p Ͻ 0.0001). Total cholesterol levels (t ϭ 3.395, df ϭ 94, p Ͻ 0.001), and LDL-C levels (t ϭ 2.420, df ϭ 94, p ϭ 0.018) were significantly higher in the longer-term treatment group. Prolactin levels were elevated (laboratory normal range, 2-20 ng/mL) in 78.6% of the sample in the short-term treatment group, and in 48.5% in the longer-term group ( 2 ϭ 7.892, p ϭ 0.019).
Mean BMI in the longer-term treatment group was significantly higher than in the short-term treatment group (see Table 5 ). BMI correlated with triglyceride levels in both groups (rho ϭ 0.304, p ϭ 0.040 in the shortterm treatment group; rho ϭ 0.414, p ϭ 0.006 in the longer-term treatment group), and with cumulative dose of SGAs (rho ϭ 0.352, p ϭ 0.005) but not FGAs. No significant differences were found when comparing BMI between patients receiving olanzapine, risperidone, or quetiapine in either of the two subgroups. There were no significant differences in blood pressure between groups.
In the longer-term treatment group, treatment with risperidone correlated with prolactin levels (rho ϭ 0.401, p ϭ 0.021) and triglyceride levels (rho ϭ 0.310, p ϭ 0.041). No other significant differences were found when comparing metabolic variables between groups treated with risperidone, olanzapine, quetiapine, or haloperidol. Also, when considering the two groups as a whole, mean prolactin levels were significantly higher among patients receiving risperidone (t ϭ 2.579, df ϭ 49.7, p ϭ 0.014), compared with those on other antipsychotics.
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DISCUSSION
The results of our study show that extrapyramidal and metabolic and endocrine side effects (such as hyperprolactinemia, lipid profile changes, and body weight gain) were more prevalent in the group of children and adolescents with longer-term antipsychotic exposure than in the group with short-term exposure to these drugs.
Abnormal involuntary movements can be detected in children and adolescents in the first days of treatment with antipsychotics, in the mild range of severity in the short-term treatment group, and they are more prevalent in patients on longer-term treatment with these drugs. Abnormal involuntary movements resembled myoclonic jerks, mainly in the perioral region and fingers and wrists, jerky protrusions and mild writhing movements of the tongue, blinking, and other tic-like movements of the neck and arms. In our sample, movements of this kind were far less common in legs and feet. Parkinsonian tremors and muscular rigidity, although these may also be present, were uncommon in these groups of patients. These types of abnormal movements, related to initiation of treatment with antipsychotic drugs, have been previously described as initial dyskinesias (Gerlach 1979) . We hypothesize that the relatively high rates of mild dyskinetic movements in the short-term treatment group could be related directly to drug exposure or that movements are exacerbated in the first days of treatment. Also, some of these patients may present mild abnormal movements spon-LAITA ET AL. 496 taneously, as has been already described. A total of 390 neuroleptic-naïve healthy children and adolescents in a foster care setting were evaluated with the Abnormal Involuntary Movement Scale (AIMS); a total of 12.6% of subjects showed mild dyskinetic movements in at least one body region, usually orofacial, and 4.1% of patients met Schooler and Kane criteria for tardive dyskinesia (Magulac et al. 1999 ).
Rates of dyskinetic movements in the shortterm treatment group of our study (5%, with at least two ratings of mild intensity) are in line with these findings. However, both our shortterm treatment patients and patients from the Magulac et al. study do not fulfill the first of these operationalized criteria, which is having received antipsychotic treatment for at least 3 months prior to assessment. The presence of abnormal movements could be associated, the authors hypothesize, with neurodevelopmental problems or social disadvantage in the study population. The higher rates, compared to the Magulac et al. study, of mild abnormal involuntary movements in body areas such as the tongue (25%, compared to 12% in their study) in our short-term treatment sample are probably in relation to the fact that our patients were not neuroleptic-naïve, and some of them were also taking other psychotropic medications at the time of evaluation. Spontaneous abnormal involuntary movements have also been described in a number of studies in medicationnaïve schizophrenic populations, and have been considered an integral part of the schizophrenia process (Khot et al. 1991; McCreadie et al. 2002) . In our short-term treatment sample, we did not find a significant association between having a psychotic disorder and the presence of involuntary movements. When comparing both groups of patients, the presence of dyskinetic type movements in the perioral region, tongue, arms, and fingers, as well as some parkinsonian signs, such as masked facial expression or hand tremors, was significantly more common in the group of patients receiving antipsychotic medication for more than 1 year. In both groups, we found a significant correlation between lifetime CPZ equivalents of antipsychotics and involuntary movements in some body parts, such as hand tremors and jerky arm movements, which could indicate differential sensitivity to the effect of these drugs. However as this is a crosssectional study, we cannot infer causality. We have not been able to determine any significant relation between side effects and other possi- ble risk factors (such as personal or familial history, age, gender, or mental retardation).
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On the other hand, 13 patients (19.7%) in the longer-term treatment group had abnormal movements of mild severity (rating of 3) in at least two body parts, but only 2 (3%) had a rating of moderate severity (rating of 4) in one body part. Both patients were also rated as presenting moderate severity on the global dyskinesia item. One of them had a diagnosis of mental retardation and the other had a diagnosis of Gilles de la Tourette's syndrome, a fact that could have influenced, by overestimation, the dyskinesia evaluation. In our opinion, based on our clinical impression, the criterion of at least one item rated as moderate severity is more accurate, in our population, for diagnosing clinically relevant tardive dyskinesia. This low prevalence is compatible with previously published data on new antipsychotic drugs (Turgay et al. 2002; Correll et al. 2004) , where the weighted mean annual incidence of tardive dyskinesia for these drugs was 0% in 77 children and adolescents on treatment with risperidone. Nevertheless, the mild dyskinetic movements observed in the sample may be a risk factor for future tardive dyskinesia, and longitudinal data are needed to determine the real prevalence and outcome of these signs. The short exposure of our patients to antipsychotics precludes us from assessing the longer-term risks of these drugs.
One relevant fact about our study sample is that there were only 10 patients with a diagnosis of co-morbid mental retardation. Several previous studies on the safety profile of antipsychotics are based on populations with this condition (Shireman et al. 2005 ) and autism spectrum disorders (Locascio et al. 1991; McDougle et al. 2005) , which are considered to have greater sensitivity to adverse motor effects of antipsychotics. Also, only 4 of our patients fulfilled criteria for attention-deficit/hyperactivity disorder (ADHD); only 12 patients had received treatment with stimulants in the past, including 4 at the time of assessment. We believe that this is a strength of our study, because in studies with high rates of concomitant treatment, side effects may be attributed to antipsychotics when they are in fact caused by other drugs (involuntary movements secondary to stimulants) widely used in the United States, where most of the previous studies were conducted.
In our sample, no statistical differences were found in the number of patients with altered metabolic parameters (fasting glucose, total and LDL-C triglycerides) between the shortterm and longer-term treatment subgroups, considering thresholds for adult population. When considering the more restrictive criteria established for pediatric populations , significantly more patients in the longer-term treatment group presented total cholesterol levels higher than 170 mg/dL, which could be related to longer treatment with antipsychotics, or be influenced by lifestyle habits or hormonal factors. No relevant abnormalities in thyroid function were observed. Although differences between groups were significant for total cholesterol and LDL-C levels, in general, these variables tended to be higher, albeit mostly within normal ranges, in the longer-term treatment group than in the shortterm treatment group. These findings could indicate a progressive change in metabolic parameters.
BMI differences found between groups, and their association with cumulative SGA dose, but not with FGA, were significant and consistent with previously published data (Stigler et al. 2004; Vieweg et al. 2005) . BMI correlated with increased appetite, which is one of the main mechanisms involved in weight gain, via drug affinity for histaminergic and alpha-1-adrenergic receptors (Baptista et al. 2004) . Also, correlation between BMI and triglyceride levels was described previously in a retrospective study with 22 patients (mean age 12.8 Ϯ 2.6 years) receiving treatment with risperidone for 4.9 months (Martin and L'Ecuyer 2002) . In that study, no significant changes were found in triglyceride and serum cholesterol levels. Despite BMI differences found between groups in our study, no significant differences were observed in high-density lipoprotein-cholesterol (HDL-C), triglyceride or glucose levels, as expected in cases of metabolic syndrome.
Overweight is one of the most prominent risk factors in the development the metabolic syndrome, but it is related to several other factors, such as hormonal parameters, dietary habits, and physical activity ). In our study, the lack of association between BMI and treatment with drugs that have been shown to have a higher risk for weight gain, such as olanzapine, may be due to the small number of patients in each treatment subgroup (possibility of type II error). Additionally, in the short-term treatment patients, exposure time to the drug was too short to detect an increase in weight, as the mean number of days was 5 and, in the longer-term treatment group, there may have been a bias in that patients who previously experienced weight gain may have been switched to the antipsychotic prescribed at the time of assessment. Increased weight in this population may have an important impact, not only on self-esteem, perception of body changes, and adherence, but on long-term consequences (Arango et al. 2004) . Surveys in different countries describe estimated prevalence of childhood obesity from 25% to 30%. After an obese child reaches 6 years of age, the probability that obesity will persist exceeds 50%, and 70-80% of obese adolescents will remain so as adults (Whitaker et al. 1997) .
Our data on serum prolactin levels are consistent with several previous studies that have reported increased prolactin levels related to antipsychotic treatment. Although all antipsychotics have been associated with this side effect, most studies to date refer specifically to the effect of risperidone on this hormone. Available data suggest that risperidone can cause hyperprolactinemia to a greater degree than other SGAs (Saito et al. 2004 ), but serum levels, which tend to increase in the first 2 months of treatment, steadily return to lower values, close to normal ranges, in 3-5 months (Findling et al. 2003) , which is consistent with our results, although a significant proportion of patients still have elevated prolactin levels. The duration of this prolactin elevation and its long-term effects in children and adolescents are unknown (Stigler et al. 2001) .
The limitations of our study include the relatively small number of patients in each group, considering the low expected prevalence of the adverse effects we are studying. This fact, together with the diversity of diagnoses and treatments in our sample, because it is a naturalistic study, makes it difficult to establish associations with possible risk factors. The small number of patients receiving treatment with FGAs in this sample makes it difficult to reach conclusions about their safety in this particular sample (greater possibility of type II error in patients treated with FGAs due to the smaller samples), or to compare them with SGAs. Because we did not include previous medications taken by patients in the analysis, this may have introduced bias in selection of patients taking specific antipsychotics at the time of assessment. Besides, the potential influence of previous treatments with FGAs in dyskinesia ratings remains uncertain in this sample. We did not record switches from other antipsychotic treatments prior to the assessment; therefore, in some cases, dyskinetic movements may have been induced by drug withdrawal. Also, this is a cross-sectional study and there may be a selection bias, with more severe patients in the longer-term group of patients. Only longitudinal studies with the same patients can assess the increased risk of these movements over time. Also, sexual side effects were not assessed in a structured way, so we could not determine any associations with prolactin levels. Regarding the IMS scale, which has shown external validity in an adult population compared to the AIMS (Cassady et al. 1997) , the sensitivity and specificity of both scales and their equivalence in a youth population have not been directly compared. In addition, validity was obtained with correlations for total symptom scores, which are less relevant than are correlations for determination of caseness of tardive dyskinesia (TD), as the data are skewed toward a large part of the population having a 0 or 1 rating. Finally, although the relatively high prevalence rates of tardive dyskinesia in our sample may be explained by the presence of spontaneous movements in this population, or influenced by the effect of concomitant medications or withdrawal of previous FGAs, it is also possible that we might have overestimated some irrelevant involuntary movements.
In summary, SGAs seem to be safe with respect to the development of tardive dyskinesia in children and adolescents. Nevertheless, mild abnormal movements may be present from the beginning of treatment, and their possible relation with progression to tardive dyskinesia remains uncertain. Metabolic and endocrine side effects, including hyperprolactinemia, increase in serum cholesterol and LDL levels, and body weight gain, are common and need to be carefully addressed. Monitoring of fasting blood glucose, serum triglyceride levels and HDL-C, blood pressure, BMI, and waist circumference are indicated The severity of the side effects that antipsychotic drugs have shown in previous studies in adults makes it necessary to be particularly careful with their appearance in this vulnerable young population, so as to optimize psychopharmacological treatments in children and adolescents.
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